Şeyma IŞIK, Berrin ERDAĞ, Aylin ÖZDEMİR BAHADIR, Bertan Koray BALCIOĞLU, Müge SERHATLI

3318

Identifying specific matrix metalloproteinase-2-inhibiting peptides through phage display-based subtractive screening

Identifying specific matrix metalloproteinase-2-inhibiting peptides through phage display-based subtractive screening

Gelatinases A and B, which are members of the matrix metalloproteinase(MMP) family, play essential roles in cancer development and metastasis, as they can break down basal membranes. Therefore, the determination and inhibition of gelatinases is essential for cancer treatment. Peptides that can specifically block each gelatinase may, therefore, be useful for cancer treatment. In this study, subtractive panning was carried out using a 12-mer peptide library to identify peptides that block gelatinase A activity (MMP-2), which is a key pharmacological target. Using this method, 17 unique peptide sequences were determined. MMP-2 inhibition by these peptides was evaluated through zymogram analyses, which revealed that four peptides inhibited MMP-2 activity by at least 65%. These four peptides were synthesized and used for in vitro wound healing using human umbilical vein endothelial cells, and two peptides, AOMP12 and AOMP29, were found to inhibit wound healing by 40%. These peptides are, thus, potential candidates for MMP2 inhibition for cancer treatment. Furthermore, our findings suggest that our substractive biopanning screening method is a suitable strategy for identifying peptides that selectively inhibit MMP-2.
PDF

___

  • Atkinson SJ, English JL, Holway N, Murphy G (2004). Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Letters 566 (1–3): 65–70. doi: 10.1016/j.febslet.2004.04.040
  • Bahadir AO, Balcioglu BK, Uzyol KS, Hatipoglu I, Sogut I et al. (2011). Phage displayed HBV core antigen with immunogenic activity. Applied Biochemistry and Biotechnology 165 (7–8): 1437–1447. doi: 10.1007/s12010-011-9365-1
  • Cao Y (2001). Endogenous angiogenesis inhibitors and their therapeutic implications. International Journal of Biochemistry and Cell Biology 33 (4): 357–369. doi: 10.1016/S1357- 2725(01)00023-1
  • Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003). Regulation of matrix metalloproteinases. An overview. Molecular and Cellular Biochemistry 253 (1–2): 269–285. doi: 10.1023/A:1026028303196
  • Cieplak P, Strongin AY (2017). Matrix metalloproteinases – From the cleavage data to the prediction tools and beyond. In Biochimica et Biophysica Acta - Molecular Cell Research 1864 (11): 1952– 1963. doi: 10.1016/j.bbamcr.2017.03.010
  • Deryugina EI, Quigley JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews 25 (1): 9–34. doi: 10.1007/s10555-006-78869
  • Dufour A, Overall CM (2013). Missing the target: Matrix metalloproteinase antitargets in inflammation and cancer. In Trends in Pharmacological Sciences 34 (4): 233–242. doi: 10.1016/j.tips.2013.02.004
  • Erdag B, Balcioglu BK, Bahadir AO, Serhatli M, Kacar O et al. (2011). Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2. Biotechnology and Applied Biochemistry 58 (6): 412–422. doi: 10.1002/bab.61
  • Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D (2008). The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Research 28 (3B): 1875–1882.
  • Guruvayoorappan C, Kuttan G (2008). Amentoflavone inhibits experimental tumor metastasisthrough a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase,VEGF, ERK-1, ERK-2, STAT1, nm23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacology and Immunotoxicology 30 (4): 711– 727. doi: 10.1080/08923970802278276
  • Huang H (2018). Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances. In Sensors (Switzerland) 18 (10): 3249. doi: 10.3390/s18103249
  • Jani M, Tordai H, Trexler M, Bányai L, Patthy L (2005). Hydroxamatebased peptide inhibitors of matrix metalloprotease 2. Biochimie, 87 (3–4): 385–392. doi: 10.1016/j.biochi.2004.09.008
  • Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP et al. (1999). Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnology 17 (8): 768–774. doi: 10.1038/11703
  • Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch Schmidtke R et al. (2004). Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nuclear Medicine and Biology 31 (3): 337–344. doi: 10.1016/j.nucmedbio.2003.10.011
  • Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS et al. (2010). p38 Mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP2 and MMP-9 activity. Cancer Research 70 (2): 832–841. doi: 10.1158/0008-5472.CAN-09-2918
  • Levin M, Udi Y, Solomonov I, Sagi I (2017). Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects. In Biochimica et Biophysica Acta - Molecular Cell Research 1864 (11): 1927–1939. doi: 10.1016/j. bbamcr.2017.06.009
  • Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL et al. (2003). Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. Journal of the Neurological Sciences 207 (1–2): 71–76. doi: 10.1016/S0022-510X(02)00398-2
  • Lu G, Zheng M, Zhu Y, Sha M, Wu Y, Han X (2012). Selection of Peptide Inhibitor to Matrix Metalloproteinase-2 Using Phage Display and Its Effects on Pancreatic Cancer Cell lines PANC-1 and CFPAC-1. International Journal of Biological Sciences 8 (5): 650–662. doi: 10.7150/ijbs.3897
  • Marqus S, Pirogova E, Piva TJ (2017). Evaluation of the use of therapeutic peptides for cancer treatment. Journal of Biomedical Science 24 (1): 1–15. doi: 10.1186/s12929-017- 0328-x
  • Nagaset H, Woessner JF (1999). Matrix metalloproteinases. In Journal of Biological Chemistry 274 (31): 21491–21494. doi: 10.1074/jbc.274.31.21491
  • Ndinguri MW, Manishabrata Bhowmick M, Tokmina-Roszyk D, Robichaud TK, Fields GB (2012). Peptide-Based Selective Inhibitors of Matrix Metalloproteinase-Mediated Activities. Molecules 17: 14230-14248. doi:10.3390/molecules171214230
  • Overall CM, López-Otín C (2002). Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nature Reviews Cancer 2 (9): 657–672. doi: 10.1038/nrc884
  • Pilcher BK, Wang M, Qin XJ, Parks WC, Senior RM et al. (1999). Role of Matrix Metalloproteinases and Their Inhibition in Cutaneous Wound Healing and Allergic Contact Hypersensitivity. Annals of the New York Academy of Sciences 878 (1): 12–24. doi: 10.1111/j.1749-6632.1999.tb07671.x
  • Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG (2020). Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics Cells 9: 1313. doi:10.3390/ cells9051313
  • Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. In Journal of Clinical Oncology 27 (31): 5287–5297. doi: 10.1200/JCO.2009.23.5556
  • Sambrook J, Aniatis T, Fritsch EF (1989). Molecular cloning : a laboratory manual Cold Spring Harbor Laboratory Press.
  • Smith GP, Scott JK (1993). Libraries of Peptides and Proteins Displayed on Filamentous Phage. Methods in Enzymology 217 (C): 228–257. doi: 10.1016/0076-6879(93)17065-D
  • Tajhya RB, Patel RS, Beeton C (2017). Detection of Matrix Metalloproteinases by Zymography. In: Charles A. Galea (Editor). Methods in Molecular Biology Humana Press, New York: NY pp. 231-244. doi: 10.1007/978-1-4939-6863-3_12
  • Tomley FM (1993). M13 phage growth and single-strand DNA preparation. In: Griffin H.G., Griffin A.M. (Editor). Methods in Molecular Biology. Humana Press, pp. 37–40. doi: 10.1385/0- 89603-248-5:37
  • Trexler M, Briknarová K, Gehrmann M, Llinás M, Patthy L (2003). Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). Journal of Biological Chemistry 278 (14): 12241–12246. doi: 10.1074/jbc.M210116200
  • Vihinen P, Kähäri VM (2002). Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. In International Journal of Cancer 99 (2): 157–166. doi: 10.1002/ijc.10329
Turkish Journal of Biology-Cover
  • ISSN: 1300-0152
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

Classification of bladder cancer cell lines according to regulon activity

Serap ERKEK-ÖZHAN, Aleyna ERAY

Fluid shear stress and endothelial cells synergistically promote osteogenesis of mesenchymal stem cells via integrin β1-FAK-ERK1/2 pathway

Mingli JIANG, Qihua SHEN, Yi ZHOU, Wenxia REN, Miaomiao CHAI, Yan ZHOU, Wen-Song TAN

Combination of classical and statistical approaches to enhance the fermentation conditions and increase the yield of Lipopeptide(s) by Pseudomonas sp. OXDC12: its partial purification and determining antifungal property

Vivek CHAUHAN, Vivek DHIMAN, Shamsher Singh KANWAR

Identifying specific matrix metalloproteinase-2-inhibiting peptides through phage display-based subtractive screening

Şeyma IŞIK, Berrin ERDAĞ, Aylin ÖZDEMİR BAHADIR, Bertan Koray BALCIOĞLU, Müge SERHATLI

A cytoplasmic escapee: desmin is going nuclear

Ecem KURAL MANGIT, Niloufar BOUSTANABADIMARALAN DÜZ, Pervin DİNÇER

Phylostat: a web-based tool to analyze paralogous clade divergence in phylogenetic trees

Ogün ADEBALİ, Elif ÖZÇELİK, Nurdan KURU